Determination of montelukast sodium by capillary electrophoresis

Shakalisava, Yuliya; Regan, Fiona

doi:10.1002/jssc.200700591

Cited by 25 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several methods have been developed to quantitatively estimate MO concentration, including voltammetry [6], capillary electrophoresis [7], spectroflurometry [8], spectrophotometry [9], and liquid chromatography (LC) [10-19]. Some of these methods were developed to monitor pharmaceutical dosage forms [14-17] and drug concentrations in biological fluids [8-13,18,19].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study

Ezzeldin

Abo-Talib

Tammam

et al. 2014

Chemistry Central Journal

View full text Add to dashboard Cite

BackgroundMontelukast is a leukotriene receptor antagonist for treatment of asthma, gliclazide is an oral hypoglycemic antidiabetic agent, and nifedipine is a calcium channel blocker used for treatment of angina pectoris and hypertension. These drugs may be prescribed to patients suffering from these chronic diseases. A survey of the literature reveals that there is no reported method for the simultaneous determination of montelukast, gliclazide, and nifedipine in pharmaceutical preparations or biological fluids.ResultsA simple, sensitive, and rapid method for the simultaneous quantification of montelukast, gliclazide, and nifedipine in human plasma was developed and validated. Montelukast, gliclazide, and nifedipine were resolved using rapid resolution LC/MS/MS Agilent system and SB-C18 (50 × 4.6 mm) 1.8 μm particle size column. The mobile phase consisted of acetonitrile: 0.1% formic acid (84:16). The three drugs were simultaneously extracted from plasma by protein precipitation with acetonitrile using zaferolukast as an internal standard. The method was validated according to FDA guidelines with good reproducibility and linearity of 0.999 and the limits of quantification were 0.11, 0.04, and 0.07 ng/mL for montelukast, gliclazide, and nifedipine, respectively. The accuracies of the three QCs for the three drugs were 99.48% (montelukast), 106.53% (gliclazide), and 108.03% (nifedipine) in human plasma. The validated method was applied to a pharmacokinetic study in human volunteers after oral administration of the three drugs. The applied LC/MS/MS method was shown to be sufficiently sensitive and suitable for pharmacokinetic studies.ConclusionThe LC/MS/MS method was validated and successfully applied for the determination of montelukast, gliclazide, and nifedipine concentrations in human plasma.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study

Ezzeldin

Abo-Talib

Tammam

et al. 2014

Chemistry Central Journal

View full text Add to dashboard Cite

show abstract

“…Several methods were developed for quantitative estimation of MO such as voltametric [10], capillary electrophoresis [12], spectroflurometry [15] spectrophotometry [17], and liquid chromatography (LC) [2–9, 11, 13, 14, 16]. Some methods were developed in pharmaceutical [11–14, 16, 17] and biological fluids [2–10, 15].…”

Section: Introductionmentioning

confidence: 99%

“…Some methods were developed in pharmaceutical [11–14, 16, 17] and biological fluids [2–10, 15]. Moreover, voltametric [10], capillary electrophoresis [12], spectrophotometry [17], spectroflurometry [15] involves tedious procedure and too many steps which do not satisfy the determination of the samples. Quantification of MO in human plasma using HPLC was developed by few authors [3–8], which involves longer run time and are more expensive.…”

Section: Introductionmentioning

confidence: 99%

Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study

Challa

Awen²,

Chandu³

et al. 2010

Sci. Pharm.

View full text Add to dashboard Cite

A simple, sensitive, and specific LC-ESI–MS/MS method for quantification of Montelukast (MO) in human plasma using Montelukast-d6 (MOD6) as an internal standard (IS) is discussed here. Chromatographic separation was performed on YMC-pack pro C18, 50 x 4.6 mm, S-3 μm column with an isocratic mobile phase composed of 10mM ammonium formate (pH 4.0):acetonitrile (20:80 v/v), at a flow-rate of 0.8 mL min−1. MO and MOD6 were detected with proton adducts at m/z 586.2→568.2 and 592.3→574.2 in multiple reaction monitoring (MRM) positive mode respectively. MO and MOD6 were extracted using acetonitrile as precipitating agent. The method was validated over a linear concentration range of 1.0–800.0 ng mL−1 with correlation coefficient (r2) ≥ 0.9996. The intraday precision and accuracy were within 1.91–7.10 and 98.32–99.17. The inter-day precision and accuracy were within 3.42–4.41% and 98.14–99.27% for MO. Both analytes were found to be stable throughout three freeze-thawing cycles, bench top, and autosampler stability studies. This method was utilized successfully for the analysis of plasma samples following oral administration of MO (5 mg) in 31 healthy Indian male human volunteers under fasting conditions.

show abstract

“…MKST is freely soluble in ethanol, methanol, and practically insoluble in acetonitrile and water. 3 The different analytical techniques reported so far for the determination of MKST in pharmaceutical formulations or in biological samples include capillary electrophoresis, 4 high performance liquid chromatography (HPLC), 5 high performance thin layer chromatography (HPTLC), 6 potentiometric titration 7 and spectrophotometry. 2 However, all these methods have several limitations.…”

Section: Montelukast Sodium (Mkst) {The Sodium Salt Of 2-[1-[[(1r)-1mentioning

confidence: 99%

Electroanalytical Characterization of Montelukast Sodium and Its Voltammetric Determination in Pharmaceutical Dosage Form and Biological Fluids

Çölkesen¹,

Öztürk²,

Erden³

2015

Journal of the Brazilian Chemical Society

View full text Add to dashboard Cite

The electrochemical properties of montelukast sodium (MKST) at zinc oxide nanoparticles modified carbon paste electrode were investigated by cyclic voltammetry and square wave voltammetry. All studies were based on the irreversible and adsorption-controlled electrochemical reduction signal of montelukast sodium at about -0.7 vs. Ag/AgCl at pH 2.3 in methanol-Britton-Robinson buffer mixture. This adsorptive character of the molecule was used to develop a novel, validated, rapid, selective and simple square wave cathodic adsorptive stripping voltammeric method for the direct determination of montelukast sodium in pharmaceutical and biological fluids without time-consuming steps prior to drug assay. Peak current of electrochemical reduction of montelukast sodium was found to vary linearly with the concentration in the range from 1.0 × 10 -8 to 1.28 × 10 -6 mol L -1 . In this method, limit of detection was found to be 7.7 × 10 -9 mol L -1 . The method was applied to determine the content of MKST tablet and spiked human serum.

show abstract

Determination of montelukast sodium by capillary electrophoresis

Cited by 25 publications

References 8 publications

Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study

Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study

Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study

Electroanalytical Characterization of Montelukast Sodium and Its Voltammetric Determination in Pharmaceutical Dosage Form and Biological Fluids

Contact Info

Product

Resources

About